Cumulative Incidence of Thromboembolism and Prognostic Impact of Stroke in BRAF V600E-mutant Non-small-cell Lung Cancer

被引:0
|
作者
Yamada, Sho [1 ]
Sekine, Akimasa [1 ]
Hagiwara, Eri [1 ]
Onodera, Yoko [1 ]
Tabata, Erina [1 ]
Ikeda, Satoshi [1 ]
Kitamura, Hideya [1 ]
Baba, Tomohisa [1 ]
Komatsu, Shigeru [1 ]
Ogura, Takashi [1 ]
机构
[1] Resp Med Kanagawa Cardiovasc & Resp Ctr, 6-16-1 Tomioka higashi, Kanazawa ku, Yokohama 2360051, Japan
关键词
Lung cancer; stroke; thromboembolism; BRAF; oncogenic driver; SUBTYPE;
D O I
10.21873/anticanres.16237
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Cancer and ischemic stroke are closely associated. Thromboembolism susceptibility in lung cancer may differ depending on oncogenic alterations. However, the clinical characteristics of thromboembolism in patients with BRAF-mutant non-small-cell lung cancer remain unknown. Thus, this study aimed to evaluate the cumulative incidence of thromboembolism in this population and describe such cases in detail. Patients and Methods: We retrospectively investigated consecutive patients with BRAF V600E-mutant non-small-cell lung cancer. Cumulative incidence was calculated using a competing risk analysis. Results: Of 10 patients with BRAF-V600E mutant lung cancer, five developed a total of seven thromboembolic events, showing a 1-year cumulative incidence of 43% (95% confidence interval=11-72%). These events consisted of four cancer-related stroke (CRS) events and three venous events including deep vein thrombosis or pulmonary embolism. Of note, most of the early thrombotic events were CRS. Two patients with CRS had multiple brain infarctions during anticancer drug therapy, characterized by high D-dimer levels, resulting in short-term mortality (13 and 22 days after stroke onset). Conclusion: A substantial proportion of patients with BRAF V600E-mutant lung cancer experienced thromboembolism during their disease course. CRS of undetermined source may predict a worse prognosis in this population.
引用
收藏
页码:935 / 938
页数:4
相关论文
共 50 条
  • [21] Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
    Xu, Ting
    Wang, Xicheng
    Wang, Zhenghang
    Deng, Ting
    Qi, Changsong
    Liu, Dan
    Li, Yanyan
    Ji, Congcong
    Li, Jian
    Shen, Lin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [22] Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
    Yuta Adachi
    Naohiro Yanagimura
    Chiaki Suzuki
    Sakiko Ootani
    Azusa Tanimoto
    Akihiro Nishiyama
    Kaname Yamashita
    Koushiro Ohtsubo
    Shinji Takeuchi
    Seiji Yano
    BMC Cancer, 20
  • [23] Effect of cyasterone on intestinal flora in a BRAF V600E-mutant mouse model of colorectal cancer
    Xiong, Ying
    Zheng, Xinyue
    Xie, Yongmei
    Gong, Youling
    Luo, Yi
    PHARMAZIE, 2022, 77 (10): : 291 - 294
  • [24] New hope for patients with BRAF V600E-mutant anaplastic thyroid cancer: lights and shadows
    Grani, Giorgio
    Filetti, Sebastiano
    Durante, Cosimo
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (08) : 2796 - 2801
  • [25] Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
    Adachi, Yuta
    Yanagimura, Naohiro
    Suzuki, Chiaki
    Ootani, Sakiko
    Tanimoto, Azusa
    Nishiyama, Akihiro
    Yamashita, Kaname
    Ohtsubo, Koushiro
    Takeuchi, Shinji
    Yano, Seiji
    BMC CANCER, 2020, 20 (01)
  • [26] Concurrent involvement of the bone marrow by BRAF V600E-mutant melanoma and hairy cell leukemia
    Moore, Margaret
    Patel, Pranav
    Tao, Jianguo
    JOURNAL OF HEMATOPATHOLOGY, 2024, 17 (04) : 223 - 225
  • [27] Liquid Biopsies for Monitoring BRAF Mutation (V600E) in Advanced BRAF (V600E) Non-Small Cell Lung Cancer (NSCLC)
    Mezquita, L.
    Jovelet, C.
    Ngocamus, M.
    Auclin, E.
    Remon, J.
    Green, E.
    Plagnol, V.
    Morris, C.
    Gazzah, A.
    Caramella, C.
    Adam, J.
    Lacroix, L.
    Friboulet, L.
    Soria, J.
    Besse, B.
    Planchard, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1843 - S1843
  • [28] Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale
    Masuishi, T.
    Taniguchi, H.
    Sugiyama, K.
    Kato, K.
    Mitani, S.
    Honda, K.
    Narita, Y.
    Kadowaki, S.
    Ura, T.
    Ando, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1330 - 1331
  • [29] BRAF Mutations in Non-Small-Cell Lung Cancer
    Smit, Egbert
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) : 1594 - 1595
  • [30] BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients
    Ahn, Hyo Yeong
    Lee, Chang Hun
    Lee, Min Ki
    Eom, Jung Seop
    Jeong, Yeon Joo
    Kim, Yeong Dae
    Cho, Jeong Su
    Lee, Jonggeun
    Lee, So Jeong
    Shin, Dong Hoon
    Kim, Ahrong
    MEDICINA-LITHUANIA, 2023, 59 (06):